Population pharmacokinetic/pharmacodynamic modeling and exposure-response analysis of ciprofol in the induction and maintenance of general anesthesia in patients undergoing elective surgery: A prospective dose optimization study

• Published in: Journal of clinical anesthesia Vol. 92; p. 111317
• Main Authors: Liu, Lu, Wang, Kun, Yang, Yuting, Hu, Mengyue, Chen, Meixia, Liu, Xiao, Yan, Pangke, Wu, Nan, Xiang, Xiaoqiang
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2024; Elsevier Limited
• Subjects: Anesthesia; Anesthesia, General - adverse effects; Anesthetics, Intravenous - adverse effects; Body Weight; Ciprofol; Clinical outcomes; Clinical trials; Drug dosages; Elective surgery; General anesthesia; HSK3486; Humans; Infusions, Parenteral; Intensive care; Normal distribution; Pain Medicine; Parameter estimation; Patients; Pharmacokinetics; PK-PD; Propofol; Prospective Studies; Variance analysis; United States > US; China; General anesthesia; Ciprofol; HSK3486; PK-PD; Elective surgery
• DOI: 10.1016/j.jclinane.2023.111317
• ISSN: 0952-8180; 1873-4529

This study aimed to establish a population pharmacokinetic and pharmacodynamic (PK-PD) model to explore the optimal maintenance dose and appropriate starting time of maintenance dose after induction of ciprofol and investigate the efficacy and safety of ciprofol for general anesthesia induction and maintenance in patients undergoing elective surgery. A total of 334 subjects with 3092 concentration measurements from nine clinical trials and 115 subjects with 5640 bispectral index (BIS) measurements from two clinical trials were used in the population PK-PD analysis. Exposure-response relationships for both efficacy endpoints (duration of anesthesia successful induction, time to recovery from anesthesia, time to respiratory recovery, and time from discontinuation to the 1st/3rd consecutive Aldrete score ≥ 9) and safety variables (hypotension, bradycardia, and injection site pain) were evaluated based on the data gathered from 115 subjects in two clinical trials. Ciprofol pharmacokinetics (PK) were adequately described by a three-compartment model with first-order elimination from the central compartment and redistribution from the deep and shallow peripheral compartments. An inhibitory sigmoidal Emax model best described the relationship between ciprofol effect-site concentrations and BIS measurements. Body weight, age, sex, blood sampling site, and study type (short-term infusion vs long-term infusion) were identified as statistically significant covariates on the PK of ciprofol. No covariates were found to have a significant effect on the pharmacodynamic (PD) parameters. The PK-PD simulation results showed that the optimal maintenance dose was 0.8 mg/kg/h and the appropriate time to start the maintenance dose was 4–5 mins after the induction dose of ciprofol. Within the exposure range of this study, no meaningful correlations between ciprofol exposures and efficacy or safety endpoints were observed. A population PK-PD model was successfully developed to describe the ciprofol PK and BIS changes. Efficacy was consistent across the exposure range with a well-tolerated safety profile indicating no maintenance dose adjustment is required for patients undergoing elective surgery. •PK-PD model used to explore optimal ciprofol maintenance dose regimen in general anesthesia for elective surgical patients•PK-PD simulations indicated the maintenance dose of 0.8 mg/kg/h given 4–5 mins after induction can maintain adequate sedation•Exposure-response analysis used to examine exposure –efficacy and safety relationships in elective surgical patients•Efficacy was high across exposure range, and together with a well-tolerated safety profile, supports current dose regimen.